Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Riot Blockchain, Inc.ex99x1.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported)   August 8, 2011
 
AspenBio Pharma, Inc.
(Exact name of Registrant as specified in its charter)

 
Colorado
 
001-33675
 
84-155338
(State or other jurisdiction of
incorporation)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)
 
 
1585 South Perry Street
Castle Rock, Colorado
 
80104
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code  (303) 794-2000
 
 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 

 
 
 
Item 7.01.  Regulation FD Disclosure.
 
The power point presentation information furnished on Exhibit 99.1 is hereby incorporated by reference under this Item 7.01 as if fully set forth herein and is available on the Company’s website. The presentation will be used for the first time at the CANACCORD/Genuity 31st Annual Growth Conference on August 9, 2011.
 
Item 9.01.  Financial Statements and Exhibits.
 
(d)  Exhibits
 
Exhibits
 
99.1
AspenBio Pharma — “Power Point Presentation” dated August 8, 2011
 
 
 
 
 
 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized
 
 
 
         
     
   
AspenBio Pharma, Inc.
         (Registrant)
 
 
 
Date:  August 8, 2011
By:  
 /s/ Jeffrey G. McGonegal  
 
   
Name:  Jeffrey G. McGonegal
 
   
Title:    Chief Financial Officer